# Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients

> **NCT01795664** · PHASE3 · COMPLETED · sponsor: **FLUIDDA nv** · enrollment: 16 (actual)

## Conditions studied

- Asthma

## Interventions

- **RADIATION:** Functional Respiratory Imaging
- **DRUG:** Salmeterol xinafoate and Fluticasone propionate HFA pMDI
- **DRUG:** Seretide Evohaler
- **DRUG:** Placebo of Test product
- **DRUG:** Placebo of Reference product

## Key facts

- **NCT ID:** NCT01795664
- **Lead sponsor:** FLUIDDA nv
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2013-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01795664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01795664, "Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01795664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*